GRCL News and Press, Gracell Biotechnologies Inc. From 05/19/21

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 PR Newswire SUZHOU, China and PALO ALTO, Calif. , May 19, 2021 ...

Gracell Biotechnologies (GRCL): Q1 GAAP EPS of -$0.05 beats by $0.16.Cash, cash equivalents and short-term investments of $331.1MPress Release For further details see: Gracell Biotechnologies EPS beats by $0.16

Reported updated long-term follow-up data for TruUCAR-enabled CD7-targeted CAR-T product candidate GC027 for the treatment of T-ALL at AACR 2021 Annual Meeting Signed agreement with Lonza to manufacture FasTCAR-enabled product candidates in the U.S. Completed initial publi...

Gracell Biotechnologies (GRCL) announces the appointment of Jenny Ni as the company's chief technology officer ((CTO)).Ni will be responsible for strategically leading CAR-T product development, Chemistry, Manufacturing, and Control ((CMC)), and supply chain management activiti...

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer PR Newswire SUZHO...

SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment ...

SUZHOU and SHANGHAI, China, April 23, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today...

Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted a...

The following slide deck was published by Gracell Biotechnologies Inc. in conjunction with this event. For further details see: Gracell Biotechnologies (GRCL) Investor Presentation - Slideshow

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting PR Newswire SUZHOU and SHANGHAI, China , April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL)...